On November 20, 2024, Jazz Pharmaceuticals announced that the bispecific antibody Zanidatamab had received accelerated approval from the FDA for the treatment of adult patients with previously treated, unresectable, or metastatic HER2-positive (HER2+, defined as IHC 3+) biliary tract cancer (BTC). Zanidatamab is the first approved HER2-targeting bispecific antibody with dual epitope specificity. On December […]
Prostate-specific membrane antigen (PSMA) is a pivotal molecular target in the treatment and diagnosis of prostate cancer (PCa). Over the past two decades, extensive research has illuminated its unique molecular characteristics, paving the way for advanced diagnostic and therapeutic approaches. PSMA-targeted imaging techniques, particularly positron emission tomography (PET) radiotracers, have demonstrated exceptional sensitivity in detecting […]
Recent advancements in the field of nuclear medicine have highlighted the significance of B-Cell Maturation Antigen (BCMA) as a pivotal target for the diagnosis and treatment of Multiple Myeloma (MM). In a groundbreaking study published in the European Journal of Nuclear Medicine and Molecular Imaging, a collaborative effort by the molecular imaging team at the First Affiliated Hospital of Jinan University and the Chinese Academy of Medical Sciences has demonstrated the efficacy of the radiolabeled antibody [89Zr]Zr-DFO-BCMAh230430 in non-invasive PET imaging of MM. This research represents a significant step forward in the development of specific immuno-PET probes targeting BCMA, which is highly expressed in malignant plasma cells.